Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)

Otsuka and Lundbeck announce the Psychopharmacologic Drugs Advisory Committee of the U.S. Food and Drug Administration met to discuss the supplemental New Drug Application of REXULTI^® (brexpiprazole) in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD).

Please click here for the full story.